Cutaneous Graft Versus Host Disease Outcomes are Similar in Haploidentical and Matched Unrelated Hematopoietic Transplant Recipients: A Retrospective Cohort Study.
Cutaneous GVHD is common post hematopoietic cell transplant. Haploidentical transplants (Haplo) have historically higher rates of GVHD with overall outcomes improved with the use of post-transplant cyclophosphamide. Specific cutaneous outcomes have not been explored in haploidentical versus matched unrelated donor transplants (MUD).To examine the incidence of GVHD in matched unrelated donor (MUD) and haploidentical (Haplo) transplants.Retrospective cohort study of patients’ records that received MUD or Haplo transplants from 2010 – 2015 with determination of GVHD severity and features by one investigator.The Haplo cohort included more minorities (22.7% vs. 6.8%; p < 0.001). Incidence of acute cutaneous GVHD was similar (Haplo 47.7% CI: 37.0-58.6 vs. MUD 42.6% CI: 37.9-47.3%; p=0.41). Chronic GVHD was also similar (Haplo 17.1%, CI 9.9-26.6 vs. MUD 12.8% CI: 9.9-16.3; p=0.31). The Haplo group had lower rates of sclerosis (13.3%, CI 1.7-4.05 vs. 50.9%, CI 37.3-64.4; p=0.0095). Other secondary outcomes showed no difference.Severity of GVHD was determined retrospectively and not all patients were seenby a dermatologist.No difference was observed between rates or severity of acute or chronic GVHD. Sclerosis was less common in the Haplo group.